Optiver Holding
IMNM icon

Optiver Holding’s Immunome IMNM Stock Holding History

Optiver Holding’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5K Buy
526
+116
+28% +$2.58K ﹤0.01% 1197
2025
Q4 		$8.81K Sell
410
-144
-26% -$2.53K ﹤0.01% 1175
2025
Q3 		$6.49K Buy
+554
New +$5.51K ﹤0.01% 1551

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Optiver Holding's IMNM Position: Q1 2026 in Review

Optiver Holding increased its Immunome (IMNM) stake by 28% in Q1 2026, buying an estimated $2.58K and bringing the position to 526 shares worth $11.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1197.

Optiver Holding first reported a position in IMNM in Q3 2025 and has held it in 3 quarters since. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Optiver Holding held 526 shares of Immunome worth $11.5K as of Q1 2026.
  • Optiver Holding bought 116 Immunome shares in Q1 2026, an estimated $2.58K.
  • Immunome made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1197 holding.
  • Optiver Holding first reported a position in Immunome in Q3 2025 and has held it in 3 quarters since.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.